{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreieiw52a7jqnndbkwmvztxfzukyssmslqpjgygj6zjpvwj3em7gsmy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mmyq4lertzn2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicnsqt2auj555z4qm5twcuncjfnuv3254ddtdrtlubz5yzvuds474"
    },
    "mimeType": "image/jpeg",
    "size": 754894
  },
  "path": "/news/2026-05-drug-outperforms-chemotherapy-patients-hard.html",
  "publishedAt": "2026-05-29T09:00:05.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins), according to new research from The University of Texas MD Anderson Cancer Center.",
  "title": "Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer"
}